

Date of Deposit: August 27, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga and Shimkets
SERIAL NUMBER: 09/494,585
EXAMINER: Christine J. Saoud
FILING DATE: January 31, 2000
ART UNIT: 1647
FOR: NOVEL FIBROBLAST GROWTH FACTOR AND NUCLEIC ACIDS ENCODING SAME

MAIL STOP IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references A4, B5-B9 and C17-C20; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.


The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-557 (Cura-57). Please address all correspondence to customer number **30623**. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor Elrifi, Reg. No. 39,529
Flora W. Feng, Reg. No. 51,673
Attorneys for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue
New York, NY 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Dated: August 27, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Prayaga and Shimkets
SERIAL NUMBER: 09/494,585 EXAMINER: Christine J. Saoud
FILING DATE: January 31, 2000 ART UNIT: 1647
FOR: NOVEL FIBROBLAST GROWTH FACTOR AND NUCLEIC ACIDS ENCODING SAME

MAIL STOP IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the International Search Report for PCT/US02/19400, which corresponds to the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Prayaga and Shimkets
U.S.S.N.: 09/494,585

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-557 (Cura-57).


Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Flora W. Feng, Reg. No. 51,673
Attorneys for the Applicant
c/o MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Dated: August 27, 2003

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/494,585
	Filing Date	01/31/00
	First Named Inventor	Prayaga
	Group Art Unit	1647
	Examiner Name	Christine J. Saoud
	Attorney Docket Number	15966-557 (Cura-57)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A4	2002/0001825	01/03/02	Itoh			04/02/01

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B5	WO	01/07595	CuraGen Corporation	February 1, 2001	X	
	B6	WO	01/68854	Amgen, Inc.	September 20, 2001	X	
	B7	WO	01/92522	Eli Lilly and Co.	December 6, 2001	X	
	B8	WO	02/02625	CuraGen Corporation	January 10, 2002	X	
	B9	WO	02/24234	The Regents of the University of California	March 28, 2002	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C17	Bange et al. (2002). <i>Cancer Res</i> 62: 840-847.					
	C18	Ohmachi et al. (2000). <i>Biochemical and Biophysical Res Comm</i> 277: 355-360.					
	C19	Wong et al. (2001). <i>Am J of Medical Genetics</i> 102: 282-285.					
	C20	International Search Report for PCT/US02/19400, mailed June 4, 2003					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.